S-1: Protagenic Therapeutics Files for Resale of 5.8 Million Shares Following Private Placement

Protagenic Therapeutics is registering the resale of 5,844,885 shares of common stock by selling stockholders, including shares issued in a recent private placement and those issuable upon exercise of warrants.

Summary

• Protagenic Therapeutics has filed a registration statement for the resale of up to 5,844,885 shares of its common stock.
• These shares include 1,948,295 shares issued in a private placement on November 4, 2024, as well as 1,948,295 shares issuable upon exercise of Series A warrants and 1,948,295 shares issuable upon exercise of Series B warrants.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders, but will receive proceeds from any cash exercise of the warrants.
• The selling stockholders may offer the shares from time to time through public or private transactions at fixed, prevailing market, related, varying, or negotiated prices.
• The registration of these shares does not guarantee that the selling stockholders will offer or sell their shares.
• The company's common stock is traded on the Nasdaq Capital Market under the symbol PTIX, with the last reported sale price on December 18, 2024, at $0.642 per share.
• The company is a biopharmaceutical company focused on developing therapeutics for stress-related neuropsychiatric and mood disorders.
• Their lead compound, PT00114, is a synthetic form of TCAP, a brain signaling peptide that can dampen overactive stress responses.
• Preclinical models have shown efficacy of PT00114 in animal models of depression, anxiety, substance abuse & addiction, and PTSD.
• The company is in the process of answering regulatory questions in the US and Germany and aims to advance PT00114 through clinical trials.

Sentiment

Score: 4

Explanation: The document highlights significant risks and financial challenges, including going concern issues and the need for additional funding. While there are positive aspects such as the novel technology and preclinical results, the overall tone is cautious due to the company's financial situation and the inherent risks of drug development.

Positives

• The company has a novel mechanism of action for its lead compound, PT00114.
• Preclinical models have demonstrated efficacy of PT00114 in animal models of depression, anxiety, substance abuse & addiction, and PTSD.
• The company owns exclusive, worldwide rights to PT00114 through a license agreement with the University of Toronto.
• Preclinical experiments required for IND filing have been completed.
• The company is in the process of answering regulatory questions in the US and Germany.

Negatives

• The company has incurred significant operating losses since inception and has an accumulated deficit of $34,749,473 as of September 30, 2024.
• The company's financial statements have been prepared on a going concern basis, and there is substantial doubt about its ability to continue as a going concern.
• The company has no approved products and has generated no product revenue.
• The company needs to obtain financing to continue operations and may not be able to obtain it on acceptable terms.
• The company's common stock is a penny stock and subject to specific rules governing its sale to investors.
• The market price of the company's common stock may be volatile.

Risks

• The company's financial statements have been prepared on a going concern basis, and there is substantial doubt about its ability to continue as a going concern.
• The company may not be able to obtain the capital necessary to fund its operations.
• The company's product candidates may not be safe or effective, or receive regulatory approval.
• The company may experience delays or difficulties in the enrollment of subjects to its clinical trials.
• The company relies on third parties for various aspects of its business, including manufacturing and clinical trials.
• The company has no experience in sales, marketing, and distribution.
• The company may not be able to gain market acceptance of its product candidates.
• The company may not be able to maintain its exclusive worldwide license to use and develop PT00114.
• The company may fail to qualify for continued listing on Nasdaq.
• The company's common stock is a penny stock and subject to specific rules governing its sale to investors.
• The market price of the company's common stock may be volatile.
• The company may fail to maintain an effective system of internal controls.
• Investors may experience dilution of their ownership interests due to future issuance of additional shares.
• The company does not intend to pay dividends for the foreseeable future.
• The company's certificate of incorporation allows for the board to create new series of preferred stock without further approval by stockholders.

Future Outlook

The company aims to rapidly advance its lead product candidate, PT00114, through clinical trials, develop additional product candidates from the TCAP family, explore efficacy in additional stress-related disorders, build a nimble team, assess strategic partnership opportunities, and strengthen its IP position.

Industry Context

The company operates in the biopharmaceutical industry, focusing on developing treatments for neuropsychiatric and mood disorders, which are areas of significant unmet medical need. The company's approach of targeting stress responses with a novel mechanism of action is aligned with current research trends in the field.

Comparison to Industry Standards

• Many biopharmaceutical companies at Protagenic's stage of development face similar challenges in securing funding and navigating the regulatory approval process.
• The company's focus on neuropsychiatric disorders is a competitive area, with several other companies also developing treatments for these conditions.
• The company's reliance on third-party manufacturers and clinical research organizations is a common practice in the industry.
• The company's need to raise additional capital is typical for early-stage biopharmaceutical companies.

Stakeholder Impact

• Shareholders may experience dilution of their ownership interests due to future issuance of additional shares.
• Shareholders may experience losses due to the volatility of the company's common stock.
• Employees may be affected by the company's financial situation and potential need to reduce operations.
• Customers (potential patients) may benefit from the development of new treatments for neuropsychiatric and mood disorders.
• Suppliers and creditors may be affected by the company's financial situation and ability to pay its obligations.

Next Steps

• The company aims to rapidly advance its lead product candidate, PT00114, through clinical trials.
• The company plans to develop additional product candidates from the TCAP family.
• The company will explore efficacy in additional stress-related neuropsychiatric and mood disorders.
• The company will facilitate long-term growth by building a nimble R&D, operational, clinical and commercial team.
• The company will proactively assess strategic partnership opportunities.
• The company will continue with its strategy of strengthening its IP position.

Key Dates

Keywords

biopharmaceutical, neuropsychiatric disorders, mood disorders, PT00114, TCAP, clinical trials, private placement, warrants, common stock, Nasdaq